Physical symptoms/side effects during breast cancer treatment predict posttreatment distress

2007 ◽  
Vol 34 (2) ◽  
pp. 200-208 ◽  
Author(s):  
Heather S. Jim ◽  
Michael A. Andrykowski ◽  
Pamela N. Munster ◽  
Paul B. Jacobsen
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Physical Symptoms ◽  
Breast Cancer Treatment

Livelihood vs. Life: The Occupational Well-Being of Women Musician Survivors of Breast Cancer

2012 ◽  
Vol 27 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Sarah Schmalenberger ◽  
Charles E Gessert ◽  
Jean E Giebenhain ◽  
Lisa D Starr
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Body Movement ◽  
Well Being ◽  
Physical Symptoms ◽  
Breast Cancer Treatment ◽  
Upper Body ◽  
Long Term Effects ◽  
Cancer Treatments

The Life and Livelihood Study was designed to describe and understand the experience of women musicians treated for breast cancer. This report focuses on Phase I of the study, a web-based survey that examined subjects’ physical symptoms and side effects following breast cancer treatment. Subjects were recruited nationally, using advertisements in musicians’ publications and presentations at national meetings. Subjects were asked about specific side effects or symptoms they had experienced, their severity and duration, and the effects of symptoms on their capacity to make music. Subjects were also asked what aspect of their breast cancer treatment they associated with each symptom and were invited to provide comments. A total of 321 individuals logged on: 100 met all inclusion criteria. Of these, 90 completed the entire survey. Commonly reported symptoms included fatigue (70%), problems with cognition (53%), limitations in upper body movement (51%), and pain (45%). Many reported that their symptoms were of moderate or greater intensity, and that they persisted for >12 months or were ongoing. The survey documented that many subjects experienced diminished capacity to function as musicians, especially due to pain, limitations in upper body and extremity movement, numbness in the chest and/or arms, contracture/fibrosis, and shortness of breath. These findings are consistent with emerging studies that describe long-term effects of breast cancer treatments. In planning for breast cancer treatment, rehabilitation and survivorship, consideration should be given to how treatment is likely to affect fitness for ongoing professional work.

Preliminary Pre-Clinical studies on the side effects of breast cancer treatment

2021 ◽  
pp. 1-41
Author(s):  
Camila Salata ◽  
Carlos E. deAlmeida ◽  
Samara C. Ferreira-Machado ◽  
Regina C. Barroso ◽  
Liebert P Nogueira ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Clinical Studies ◽  
Breast Cancer Treatment

CARBON NANOHORN AS NANOCONTAINER FOR CISPLATIN: INSIGHTS ON THE INTERACTION WITH PLASMA MEMBRANES OF NORMAL AND BREAST CANCER CELLS

2021 ◽  
Author(s):  
Eduardo Ribeiro Almeida ◽  
Helio F. Dos Santos ◽  
Priscila V. S. Z. Capriles
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Plasma Membranes ◽  
Breast Cancer Treatment ◽  
Therapeutic Alternatives

Cisplatin (cddp)-based chemotherapy is one of the most effective therapeutic alternatives for breast cancer treatment, the most common form of cancer, despite the severe side effects related to the high...

Acupuncture for Treating Common Side Effects Associated With Breast Cancer Treatment: A Systematic Review

2010 ◽  
Vol 22 (2) ◽  
pp. 81-97 ◽  
Author(s):  
Stephanie Dos Santos ◽  
Nancy Hill ◽  
Ashley Morgan ◽  
Jenna Smith ◽  
Carolyn Thai ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Side Effects ◽  
Cancer Treatment ◽  
Breast Cancer Treatment

scholarly journals Efficacy and safety of Nab-paclitaxel in breast cancer: a meta-analysis

2019 ◽  
Author(s):  
Upendra Yadav ◽  
Pradeep Kumar ◽  
Vandana Rai
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Side Effects ◽  
Cancer Treatment ◽  
Meta Analysis ◽  
Progression Free Survival ◽  
Breast Cancer Treatment ◽  
Efficacy And Safety ◽  
Free Survival ◽  
Key Terms

AbstractWorldwide breast cancer is the leading cause of cancer related death in women. Paclitaxel is an effective drug used for the treatment of breast cancer but it has many side effects. Nab-paclitaxel (nanoparticle albumin-bound paclitaxel) is an FDA approved drug for the treatment of breast cancer. Currently many clinical trials are conducted to deliver nab-paclitaxel into the tumor cells. But the efficacy and safety of this nab-paclitaxel over conventional paclitaxel still remains questionable. So, we performed a meta-analysis to evaluate the efficacy and safety of nab-paclitaxel in breast cancer treatment.Electronic databases were searched for the suitable studies using key terms “nab-paclitaxel”, “paclitaxel”, and “clinical trial” with the combination of “breast cancer” up to August 11, 2019. Risk ratio (RR) and odds ratio (OR) with corresponding 95% confidence intervals (CIs) were calculated. All statistical analyses were performed by the Open Meta-Analyst program. A total of eight studies which fulfilled our criteria were included in this study. For efficacy we retrieved data of 12 months progression free survival, 24 months progression free survival, and overall survival (up to 3 years) and for the safety we took data of nausea, anemia, leukopenia, neutropenia, fatigue, diarrhea and pain.We did not found any difference in efficacy of nab-paclitaxel over paclitaxel (12 months progression free survival-RRFE= 0.86, 95%CI= 0.77-0.97, p= 0.02, I2= 25.07%; 24 months progression free survival-RRFE= 0.86, 95% CI= 0.64-1.16, p= 0.34, I2= 0%; and 3 years survival-RRFE= 1.20, 95%CI= 0.92-1.56, p= 0.16, I2= 37.55%). The meta-analysis of studies used nab-paclitaxel showed reduced adverse effect of anemia (ORFE= 1.66, 95% CI= 1.26-2.19; p= <0.001; I2= 0%) and leukopenia (ORFE= 1.37; 95%CI= 1.06-1.75; p= 0.01; I2= 48.63%). However, in case of other adverse effects no significant association was found with nab-paclitaxel (nausea-ORFE=1.15, 95%CI= 0.94-1.41, p= 0.15, I2= 50.12%; neutropenia-ORRE= 0.75, 95%CI= 0.30-1.87, p= 0.54, I2= 94.45%; fatigue-ORRE= 1.11, 95%CI= 0.77-1.62, p= 0.55, I2= 56.02; diarrhea-ORFE= 1.11, 95%CI= 0.77-1.62, p= 0.55; I2= 34.26; pain-ORRE= 1.15, 95%CI= 0.78-1.69, p= 0.45, I2= 52.96%).In conclusion the use of nab-paclitaxel has reduces the side effects of anemia and leukopenia in breast cancer treatment in comparison to paclitaxel but nab-paclitaxel has no effect on the overall survival of the patients.

Assessment of combination approaches of phytoconstituents with chemotherapy for the treatment of breast cancer, a systematic review

2021 ◽  
Vol 27 ◽  
Author(s):  
Ali Sartaj ◽  
Sanjula Baboota ◽  
Javed Ali
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Side Effects ◽  
Cancer Treatment ◽  
Conventional Treatment ◽  
Breast Cancer Treatment ◽  
Chemotherapeutic Agents ◽  
Multi Drug Resistance ◽  
High Dose ◽  
Effective Strategy

Purpose: The available conventional treatment for breast cancer, like surgery, hormonal, radiation, and chemotherapy, given alone or in combination, is commonly used. Due to broad and diverse side effects, toxicity, and multi-drug resistance, chemotherapy has limited use and less effective treatment. In this review, anti-cancer drugs used in combination with phytoconstituents approaches have been summarised. It has been anticipated that this could be a promising and effective strategy for breast cancer treatment. Methods: This review is conducted based on relevant literature using the keywords presented in the title, abstract, and keywords. The available literature search in PubMed, ScienceDirect, MedlinePlus, and Google scholar up to May 2021. A total of 47 articles were selected out of 168 articles based on inclusion and exclusion criteria. Results: The significant drawbacks of available conventional treatment, especially chemotherapy, are low bioavailability for absorption at the specific site of tumor cells, development of multi-drug resistance, and high dose-related to various side effects. The phytoconstituents have anticancerous properties and chemotherapeutic agents that find a promising and potential therapeutics modality. Many in vitro and in vivo studies showed that phytoconstituents could enhance the effectiveness of chemotherapy drugs for breast cancer treatment. Conclusion: The combination approaches of phytoconstituents with chemotherapeutic drugs give less toxicity to normal cells, reduce side effects, and overcome the multi-drug resistance, making the combination approaches an effective strategy.

scholarly journals PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH BREAST CANCER – A CROSS-SECTIONAL STUDY

2018 ◽  
Vol 24 (5) ◽  
pp. 377-381
Author(s):  
Leonessa Boing ◽  
Gustavo Soares Pereira ◽  
Melissa de Carvalho Souza Vieira ◽  
Taysi Seemann ◽  
Allana Alexandre Cardoso ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Physical Activity ◽  
Side Effects ◽  
Cancer Treatment ◽  
Vigorous Physical Activity ◽  
Breast Cancer Treatment ◽  
Clinical Treatment ◽  
Walking Time

ABSTRACT Introduction: Breast cancer treatment can cause different side effects on the quality of life of women. Physical activity, in turn, can reduce these side effects. Objective: To investigate the physical activity and quality of life of women during and after breast cancer treatment. Methods: Sample of 174 women (57.0±9.5 years) during or after clinical treatment for breast cancer. Interview questionnaire composed of general information, physical activity (IPAQ short version) and quality of life (EORTC QLQ-C30 and BR23). For statistical analysis chi-squared test or Fisher's exact test, student's t-test for independent samples, Mann-Whitney U test and multiple logistic regression analyses (p <0.05). Results: Most women did not achieve the physical activity guidelines, particularly those undergoing clinical treatment. Results showed longer walking time, moderate physical activity, vigorous physical activity, moderate + vigorous physical activity, and total physical activity among the women following completion of treatment. The quality of life scores were also higher among women after clinical treatment. Logistic regression indicated that every 10-minute increment to walking time results in a 19% decrease in the probability of worse functional capacity and a 26% decrease in the probability of worse symptoms associated with treatment side effects. Conclusion: During treatment, women with breast cancer undertake less physical activity and have worse quality of life. Walking appears to be an effective type of physical activity for these women, improving quality of life during and after breast cancer treatment. Level of evidence II; Prognostic studies - Investigation of the effect of patient characteristics on the disease outcome.

Sign in / Sign up

Export Citation Format

Share Document